답손
Dapsone
4,4'-diaminodiphenyl sulfone
다른 이름: Avlosulfone · Dapsoderm-X · Dopsan · Novasulfone · Servidapsone · Sulfona · DADPS · dapsonum · DDS · diaminodiphenylsulfone · NSC-6091 · diaphenylsulfone · disulone · sulfonyldianiline
VetSheet 수의사 팀 검수업데이트 2026년 4월 5일근거 기반 수의학 참고자료
용량은 수의사 전문가를 위한 임상 참고자료입니다. 반드시 최신 약물 정보 및 개별 환자에 따라 확인하시기 바랍니다.
동물 종별 용량
🌎 NA — North America🌍 EU — Europe
개
| 적응증 | 용량 | 경로 | 빈도 | 기간 | 지역 |
|---|---|---|---|---|---|
| Alternative treatment for pemphigus | 1 mg/kg PO q8h; with sulfasalazine at 10-40 mg/kg q8h | PO | q8h | — | 🌎 NA |
| Post-vaccination alopecia/vasculitis resistant to prednisone therapy | 1 mg/kg PO q8h | PO | q8h | — | 🌎 NA |
| Treating mycobacteriosis | 1.1 mg/kg PO q6h until remission, then 0.3 mg/kg q8-12h after recovery | PO | q6h initially, then q8-12h | Until remission, then maintenance | 🌎 NA |
| Adjunctive therapy of vasculitis | 1 mg/kg PO q8h | PO | q8h | — | 🌎 NA |
| Adjunctive treatment of Brown Recluse spider (Loxosceles spp.) bite | 1 mg/kg PO three times daily for 10 days | PO | TID | 10 days | 🌎 NA |
고양이
| 적응증 | 용량 | 경로 | 빈도 | 기간 | 지역 |
|---|---|---|---|---|---|
| Alternative to clofazimine for treating feline leprosy | 1 mg/kg once daily PO | PO | q24h | — | 🌎 NA |
| Treating mycobacteriosis | 8 mg/kg PO once daily for 6 weeks | PO | q24h | 6 weeks | 🌎 NA |
| Aural chondritis | 1 mg/kg PO q24h | PO | q24h | — | 🌎 NA |
- Alternative to clofazimine for treating feline leprosy: Caution: High risk of serious side effects. Intensive monitoring required.
- Treating mycobacteriosis: Caution: High risk of serious side effects. Intensive monitoring required.
- Aural chondritis: Caution: High risk of serious side effects. Intensive monitoring required.
말
| 적응증 | 용량 | 경로 | 빈도 | 기간 | 지역 |
|---|---|---|---|---|---|
| Alternative treatment for Pneumocystis carinii pneumonia | 3 mg/kg PO once daily (q24h) | PO | q24h | 56 days | 🌎 NA |
- Alternative treatment for Pneumocystis carinii pneumonia: From one case report of treatment of a foal.
용량은 수의사 전문가를 위한 임상 참고자료입니다. 반드시 최신 약물 정보 및 개별 환자에 따라 확인하시기 바랍니다.
개요
답손(Dapsone)은 설폰계 항균제 및 항염증제입니다. 수의학에서는 주로 특정 면역 매개성 피부 질환(예: 천포창, 피부 혈관염) 및 비정형 감염(예: 마이코박테리아, 폐포자충)에 대한 2차 또는 보조 요법으로 사용됩니다.
임상 요점: 간독성 및 혈액 질환과 같은 심각한 부작용 발생 위험이 높기 때문에 1차 선택약으로 사용되는 경우는 드뭅니다. 고양이는 메트헤모글로빈혈증 및 용혈성 빈혈에 대한 감수성이 매우 높으므로 고양이에게는 상대적 금기로 간주됩니다.
작용 기전
Antimicrobial action: Acts as a competitive antagonist of para-aminobenzoic acid (PABA). It inhibits the enzyme dihydropteroate synthase (DHPS) → blocks the synthesis of dihydrofolic acid → disrupts nucleic acid synthesis in susceptible organisms (similar to sulfonamides).
Anti-inflammatory action: Dapsone exerts potent immunomodulatory effects. It inhibits the myeloperoxidase-H2O2-halide system → suppresses the neutrophil respiratory burst. It also decreases neutrophil chemotaxis, complement activation, antibody production, and lysosomal enzyme synthesis, making it useful for sterile, neutrophil-driven inflammatory conditions like vasculitis or Brown Recluse spider bites.
안전성·주의사항
금기사항
- Cats (relatively contraindicated due to high risk of neurotoxicity and hemolytic anemia)
- Hypersensitivity to dapsone or other sulfone drugs
- Patients with severe anemias or preexisting blood dyscrasias
- Preexisting hepatic dysfunction (use with extreme caution)
부작용
- Hepatotoxicity
- Dose-dependent methemoglobinemia
- Hemolytic anemia
- Thrombocytopenia
- Neutropenias
- Gastrointestinal effects (nausea, vomiting)
- Neuropathies
- Cutaneous drug eruptions
- Photosensitivity
- Potential carcinogen
주의
- Feline Sensitivity: Cats are highly susceptible to dapsone-induced blood dyscrasias and hepatotoxicity. Use is generally not recommended.
- Pregnancy: FDA Category C. Animal studies have shown adverse effects on the fetus. Use with caution in pregnant animals.
- Nursing: Excreted into milk in concentrations equivalent to plasma; hemolytic reactions have been seen in human neonates. Consider switching to milk replacer if required in a nursing dam.
- Hepatic Disease: Use with caution in animals with preexisting hepatic dysfunction due to hepatotoxic potential.
약물 상호작용
May decrease the renal excretion of active metabolites of dapsone.
May increase risk of hematologic reactions occurring with dapsone.
May decrease plasma dapsone concentrations (7-10 fold).
May increase plasma dapsone concentrations (and vice versa) and potentially increase each other's toxicity.
모니터링
- CBC with platelets every 2-3 weeks during first 4 months of treatment, then every 3-4 months
- Liver function tests
- Clinical signs of adverse effects (GI upset, drug eruptions, neurotoxicity, jaundice, cyanosis)
- Clinical efficacy
약동학
반감기
흡수
Rapidly and completely absorbed after oral administration to dogs.
분포
In dogs, the monoacetyl metabolite is only about 60% bound to plasma proteins (compared to almost completely bound in humans).
대사
Hepatic metabolism, primarily via acetylation.
배설
Primarily eliminated via the kidneys as conjugates and unidentified metabolites.
과다투여
Because of its toxicity potential, specific species differences in sensitivity, and pharmacokinetics, it is recommended to contact an animal poison control center in cases of dapsone overdoses.
- Clinical Signs: In humans, overdoses generally cause nausea, vomiting, and hyperexcitability within minutes. Methemoglobinemia with associated depression, seizures, and cyanosis can occur. Hemolysis may be delayed, occurring 7-14 days after the overdose.
- Treatment: Includes removal of drug from the gut (decontamination), methylene blue for methemoglobinemia, and sometimes hemodialysis to enhance removal of the drug and its monoacetyl metabolite.
제품
제형
- Oral Tablets
- Compounded oral suspension
인용의약품
- Dapsone Oral Tablets: 25 mg & 100 mg (scored)
규제 현황
규제 데이터 없음: 🇺🇸 US · 🇪🇺 EU · 🇬🇧 UK · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
보관·안정성
Store tablets protected from light at controlled room temperature (20-25°C, 68-77°F). Tablets may be compounded into a stable liquid dosage form (2 mg/mL) using a 1:1 ratio of Ora-Plus:Ora-Sweet; this preparation is stable for 90 days stored refrigerated or at room temperature.
보호자 정보
- 엄격한 모니터링: 이 약물은 수의사의 세심한 감독이 필요합니다. 반려동물의 간 및 적혈구 상태를 확인하기 위해 빈번한 혈액 검사가 필수적입니다。
- 독성 징후 주의: 창백하거나 푸르스름한 잇몸, 눈/피부의 황달, 극심한 무기력, 빠른 호흡, 구토 또는 비정상적인 쇠약이 관찰되면 즉시 수의사에게 연락하십시오。
- 자외선 차단: 답손은 광과민성을 유발할 수 있습니다. 노출된 피부가 장시간 햇빛에 노출되지 않도록 보호하십시오。
- 고양이 사용 경고: 고양이에게 처방된 경우, 심각한 부작용의 위험이 매우 높다는 점을 이해하셔야 합니다.
VetSheet 의약품 참고자료는 수의사 전문가의 임상 의사결정 지원을 위한 것이며, 전문적 판단이나 제조사의 최신 약물 정보를 대체할 수 없습니다.